bbc - Abiraterone will be available in a matter of weeks and will be offered to 7,000 men a year.
AI Summary: Health authorities in England have announced that nearly 7,000 additional men with hormone‐sensitive prostate cancer will soon be eligible for abiraterone—a breakthrough treatment that extends survival. The drug is expected to be available within weeks, marking a significant step forward in targeted prostate cancer care.
DEA extends telehealth controlled substance flexibilities for 2026 / 4 months
FDA Removes Warning Labels on Menopause Hormone Therapies / 6 months
AbbVie sues over Botox selection in Medicare price negotiations / 3 months
HHS drops 340B pilot following court rulings / 3 months
HHS scraps 340B rebate pilot following court rulls / 3 months
FTC settles insulin lawsuit forces Express Scripts policy changes / 3 months
Judge blocks 340B drug pricing pilot program implementation / 4 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.